Transgenic shuttle vector assays for assessing oxidative B-cell mutagenesis in vivo.
The recent development of transgenic mutagenicity assays provides new opportunities for evaluating mutagenic processes in vivo. To asses mutant frequencies in tissue B cells, we decided to take advantage of two such assays that utilize the transgenic shuttle vectors, lambda LIZ and pUR288. Our main interest in this research is to test two basic premises of inflammation-induced plasmacytoma development in genetically susceptible BALB/c mice; i.e., the possibility that plasmacytoma precursor cells may become targets of phagocyte-mediated oxidative mutagenesis in situ and the prospect that plasmacytoma susceptibility/resistance genes may contribute to these phenotypes by enhancing/reducing oxidative mutagenesis in B cells. Based on our preliminary experience with the lambda LIZ and pUR288 transgenic in vivo mutagenicity tests, we propose to employ these assays as broadly applicable tools for assessing overall mutagenesis during normal and aberrant (malignant) B-cell development. Furthermore, transgenic shuttle vector assays appear to lend themselves as ideal methods to associate general B-cell mutagenesis with the peculiar, B cell-typical somatic hypermutation processes that target the V(D)J gene segment, the proto-oncogene bcl-6 and perhaps other, still unknown loci.
Laboratory of Genetics, NCI, NIH, Bethesda, MD, USA.
K
K
Felix
K
K
Kelliher
G W
GW
Bornkamm
S
S
Janz
D000818:Animals; D001402:B-Lymphocytes / Q000378:metabolism*; D010582:Bacteriophage lambda / Q000235:genetics; D005822:Genetic Vectors; D051379:Mice; D009154:Mutation; D010084:Oxidation-Reduction; D010586:Phagocytes / Q000378:metabolism; D010954:Plasmacytoma / Q000235:genetics / Q000378:metabolism; D010957:Plasmids / Q000235:genetics